These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19273457)

  • 1. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
    Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
    Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum soluble CD40 levels in patients with systemic sclerosis.
    Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
    Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.
    Dziadzio M; Smith RE; Abraham DJ; Black CM; Denton CP
    Rheumatology (Oxford); 2005 Dec; 44(12):1518-24. PubMed ID: 16159952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study.
    Iannone F; Matucci-Cerinic M; Falappone PC; Guiducci S; Cinelli M; Distler O; Lapadula G
    J Rheumatol; 2005 Oct; 32(10):1893-8. PubMed ID: 16206343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
    Bevelacqua V; Libra M; Mazzarino MC; Gangemi P; Nicotra G; Curatolo S; Massimino D; Plumari A; Merito P; Valente G; Stivala F; La Greca S; Malaponte G
    Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity.
    Yoshizaki A; Iwata Y; Komura K; Hara T; Ogawa F; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Sep; 35(9):1825-9. PubMed ID: 18688912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
    Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
    Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.